Antiphospholipid Syndrome Market Is Expected To Grow During the Study Period (2019-2032), DelveInsight | Key Companies- Genentech Inc, Bayer, and Several Others

"Antiphospholipid Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market"

Antiphospholipid Syndrome Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. The detailed market research, industry sector growth and development, and new product introductions covered in this report on the Antiphospholipid Syndrome Market are of great assistance to the important new commercial players joining the market.

Key takeaways from Antiphospholipid Syndrome Market Report
• According to a study conducted by García et. al. (2019), the annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42-58) per 100,000 population.
• According to a study by D'Cruz et. al. (2019), prevalence in the UK peaked at 50 (95% CI 49 - 55) in females in 2011 and 9.8 (95% CI 8.6 - 11.1) per 100,000 in males in 2012.
• According to a study by Radin et. al. (2020), the prevalence cases of Antiphospholipid antibody syndrome in Italy are 40-50 cases per 100,000 persons and the diagnosis rate of Antiphospholipid antibody syndrome in Italy were 63% in aged of ≤50 years, 39% ≤40 years, and 18% ≤30 years.
• Antiphospholipid Syndrome Market Companies included Genentech Inc, Bayer, LumiraDx UK Limited, Intermountain Health Care Inc., University of Utah, Bristol-Myers Squibb, Scott C, Hoffmann-La Roche, and several others.
• Antiphospholipid Syndrome Market Therapies included Rituximab, CoaguChek XS, Standard Lab Draw, Apixaban, Warfarinm, Rivaroxaban, and several others.

Get to know more information of the Antiphospholipid Syndrome Market Companies- https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Antiphospholipid Syndrome Overview
Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease which can cause frequent clotting in arteries and veins and/or miscarriages. The clotting results from the presence of proteins in the blood called anti-phospholipid autoantibodies (commonly called aPL) formed against the person's own tissues.

Antiphospholipid Syndrome Epidemiology Insights
According to American College of Rheumatology (2021) it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men. For arterial events, recurrences are also prevented with drugs that inhibit platelets, such as aspirin and clopidogrel (Plavix) and for pregnancy related events subcutaneous injections of heparin and low-dose aspirin are the standard therapy for preventing miscarriages.

Antiphospholipid Syndrome Epidemiology Segmentation in the 7MM
• Total Antiphospholipid Syndrome Prevalence Case
• Antiphospholipid Syndrome Age-specific Cases
• Antiphospholipid Syndrome Clinical Manifestations
• Antiphospholipid Syndrome Gender-specific Cases
• Antiphospholipid Syndrome Diagnosed and Treatable Cases

Discover more information of the Antiphospholipid Syndrome Epidemiology Segmentation - https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Antiphospholipid Syndrome Treatment Market
Currently, treatment of patients with Antiphospholipid syndrome is based on long-term oral anticoagulation therapy for thrombotic manifestations and the combination of low dose aspirin (LDA) and low-molecular-weight heparin (LMWH) to prevent obstetric manifestations. However, the lack of well-designed studies means that the strength of some recommendations is debatable. Innovative therapeutic approaches, such as immune modulation, complement inhibition, and targeting inflammation, are under study. Further mechanistic and clinical studies are needed to develop improved therapies for this potentially devastating illness. Better understanding of the pathophysiological mechanisms of Antiphospholipid syndrome will help to identify new therapeutic targets, and a balance between anticoagulation and immunomodulatory drugs for different Antiphospholipid syndrome manifestations.

Antiphospholipid Syndrome Market Insights
Low dose aspirin (LDA) and Low-molecular-weight heparin (LMWH) used in thrombotic Antiphospholipid syndrome women. Sometime LMWH is used with or without aspirin throughout pregnancy. LMWH acts through mechanisms alternative to its well-known anticoagulant effect, because of its ability to bind β2GPI. For those patients with purely obstetric APS and no prior thrombosis (OAPS), prophylactic dose LMWH and LDA until 6 weeks postpartum is recommended.

Antiphospholipid Syndrome Market Forecast
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

Antiphospholipid Syndrome Market Drivers
• Increase in awareness
• Increase in R&D of diagnostic tools leads to better diagnosis of the disease
• Increasing Prevalence of the Disease

Antiphospholipid Syndrome Market Barriers
• Off-label drugs usage
• Lack of emerging therapies
• Lack of management of Disease

Download a PDF Sample Report of Antiphospholipid Syndrome Market Outlook Report- https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis for Antiphospholipid Syndrome
4. Antiphospholipid Syndrome Market Overview at a Glance
5. Antiphospholipid Syndrome Disease Background and Overview
6. Patient Journey
7. Antiphospholipid Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Antiphospholipid Syndrome Unmet Needs
10. Key Endpoints of Antiphospholipid Syndrome Treatment
11. Antiphospholipid Syndrome Marketed Products
12. Antiphospholipid Syndrome Emerging Therapies
13. Antiphospholipid Syndrome Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Antiphospholipid Syndrome Market Outlook
16. Access and Reimbursement Overview of Antiphospholipid Syndrome
17. KOL Views
18. Antiphospholipid Syndrome Market Drivers
19. Antiphospholipid Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Find out the related information on Antiphospholipid Syndrome Mergers and acquisitions, Antiphospholipid Syndrome Licensing Activities @ Antiphospholipid Syndrome Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.